Webinar - Development of Covalent Drugs with New Emerging Technologies

Covalent drugs could provide pharmacological advantages like prolonged duration of action and enhanced potency over non-covalent drugs. In recent years, their discovery has been boosted by rational design and facilitated by emergence of new technologies in proteomics. This enables drug identification with higher selectivity by identifying their binding site.
With their unique mechanistic properties that differentiate them from non-covalent inhibitors, covalent drugs can be administered at lower doses and frequencies reducing off-target events and increasing patients’ compliance. In addition, they can be an effective strategy for low vulnerability targets where high levels of occupancy are needed to generate the desired physiological outcomes. Covalent therapeutics can also be a strategy to overcome drug-resistance mutations in the gene encoding the target protein like in case of the epidermal growth factor receptor (EGFR).
Join this webinar to learn more about the new emerging technologies to develop covalent therapeutics.
#Drug Resistance #Therapeutics #Proteomics #Covalent Drugs